Activist Fivespan has a stake in Qiagen. Here are 3 levers to boost the company's growth and improve value
Stock Market Value: $9.32B ($43.13 per share)
Ownership: n/a
Average Cost: n/a
Activist Commentary: Fivespan Partners, LP is a San Francisco-based investment firm founded by Dylan Haggart and Sarah Coyne. Prior to Fivespan, Haggart and Coyne were partners at ValueAct Capital and most of the investment team is from ValueAct. Fivespan, named after the unique five-stone arched bridge in Haggart's hometown, views itself as a bridge between the market and companies. The firm prefers behind-the-scenes, collaborative and amicable activism, but it would resort to a proxy fight if it had no other choice. We believe that the firm would look for board seats in situations where it thinks it could add real value, but we do not expect Fivespan to pursue board representation as often as ValueAct does (i.e, roughly 50% of core portfolio positions). Haggart certainly has experience as a public company director. He served as a director of Seagate (2018 to the present) and Fiserv (2022 to 2024), at which he has delivered stellar returns over his tenures of 44.45% and 64.68%, respectively, versus 17.36% and 4.98% for the Russell 2000. Additionally, Haggart was an advisor to Seagate going back as far as 2016, over which time the company returned about 222%. Fivespan looks for high quality, idiosyncratic businesses with good, strategic assets. The firm does not advocate for the sale of its portfolio companies as a primary activist strategy, but like companies that people want to own. Accordingly, many of the firm's activist campaigns could end with a sale of the company, providing two paths to shareholder value. The fund is a drawdown structure that holds investments for at least three to five years, aims to have six to eight investments at a time and averages $100 million to $300 million in each investment.
Fivespan Partners has built a position in Qiagen NV and has engaged in conversations with management.
Qiagen is a Netherlands-incorporated life sciences tools firm, dual-listed in the U.S. and Germany. The company provides sample technologies to isolate and process DNA, RNA and proteins; assay technologies to prepare these biomolecules for analysis; and automation solutions to bring these processes together. The company has two primary end markets from which it derives a balanced share of its revenue: Molecular Diagnostics (health-care providers) and Life Sciences (pharma/biotech research and other lab applications). It operates in an extremely attractive and growing industry with high returns on invested capital (ROIC) and margins. Qiagen specifically enjoys a leading market position, has a great brand reputation and favorably derives about 90% of its sales from recurring consumables revenue, with the remainder from the sale of its instruments and related services, a razor-razorblade model. Despite its dual-listing and European heritage, Qiagen's chairman and CEO are based in the U.S., and it generated 52% of its FY24 sales in North America, 32% in Europe, the Middle East and Africa, and 16% in Asia.
Fivespan looks for high quality, idiosyncratic businesses with good, strategic assets, and Qiagen fits this thesis nicely – a high-quality health-care business in a growing industry with secular tailwinds. However, despite having a respected name and a strong market position, the company has struggled to create shareholder value post-Covid, delivering 1-, 3-, and 5-year returns of 1%, -6%, and 1%, respectively. While peers trade at around 15 times EV/EBITDA, and leaders like Danaher 20 times, Qiagen currently trades at around 13 times. This contrasts with the stock historically trading at a significant multiple to peers.
Management has done the hard things right: investing in R&D, listening to the customers, and protecting the company's industry-leading brand, growing its topline at a 5.3% compound annual growth rate from 2019 to 2024. Now there is an opportunity to grow even faster and in a more focused manner. In an attempt to empire-build, Qiagen has lost sight of the core business, investing a lot in the diagnostics business and other ventures when the life sciences business has a superior return on invested capital. There are three levers to create shareholder value here. First, management should invest in and around its core business to accelerate growth. Moreover, they should not keep their plan a secret but communicate it better to the market. Second, Qiagen can be run a lot tighter, leaving room for margin expansion. Currently running at a 25% operating margin, a more disciplined approach could achieve operating margins upward of 30%. Third, Qiagen's balance sheet could be optimized. Most of its peers have far more leverage and should, due to the recurring nature of the business, yet the company has $1.15 billion of cash and short-term investments, $1.39 billion of debt and no good acquisition targets on the horizon. By levering up, Qiagen could fund additional investments in its core business and buy back some of its own stock at attractive prices ahead of growth and margin improvements. It is not often that there are opportunities for both revenue growth and margin expansion at the same time. When you have a situation like that, it certainly makes sense to buy back your own shares ahead of it.
Based on its activist philosophies, we would expect that Fivespan has had a position in Qiagen for some time and has been trying to work with management behind the scenes. The firm is a quiet investor and does not publicize its positions (i.e., this is one of six current positions and the only one known publicly). We think the company may not be playing as amicably as Fivespan. An indication of this is that, perhaps in response to Fivespan's engagement, the company recently pre-announced a beat for its Q1 results and raised expectations regarding its margins, targeting above 30% for the year and over 31% ahead of its 2028 timeline. Qiagen also put out a press release describing its product pipeline, nothing new per se, but a clear sea change in terms of its management of investor communications and proactive strategic planning. There are several ways this can go. Management can agree to embrace Fivespan, who is not advocating for any real controversial actions – growth and margin improvement, the same thing management wants. Management can ignore but placate the investor by taking actions consistent with the plan that results in shareholder appreciation. Or management can ignore the firm and continue down the same road with a flat stock price performance. Given that we do not expect that Fivespan will aggressively pursue a board seat here, we think the first option is preferable, the second is tolerable and the third is unacceptable. Often the tone of an activist campaign depends not on the activist, but the response of the company. This scenario could be a perfect example of that.
As mentioned before, Fivespan appreciates businesses with several paths to shareholder value, one of them being strategic transactions. Qiagen is a highly attractive asset. In fact, pre-Covid, the company held discussions with several suitors regarding a potential transaction. In 2020, they agreed to an improved offer of 43 euros per share from Thermo Fisher Scientific, but the deal ultimately collapsed after Thermo failed to reach the two-thirds tender offer threshold, in part due to a Covid-induced run-up in the share price and vocal shareholders like Davidson Kempner coming out against the deal. Today, the business is just as strong, if not stronger, and FY25 EPS is expected to come in higher than it was in 2020. A sale is never Fivespan's first choice when making an investment. The firm will focus on the operational and allocation improvements available to create shareholder value but evaluate that against any potential acquisition offer the company may receive and advocate for what it thinks is best for shareholders. With strategic and respected assets – and with the stock trading slightly below the previous offer price from five years ago – an unsolicited offer for the company is not outside of the realm of possibility.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
an hour ago
- Business Insider
Upcoming Stock Splits This Week (August 18 to August 22)
These are the upcoming stock splits for the week of August 18 to August 22, based on TipRanks' Stock Splits Calendar. A stock split boosts the number of shares each investor holds, but the company's overall market value remains exactly the same. The effect is a lower share price, which often makes the stock more affordable and appealing to retail investors. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Traditional stock splits are designed to broaden a stock's accessibility by reducing its price per share. But some companies take the opposite route through a reverse stock split. In this case, shares are consolidated rather than divided, reducing the total count and raising the price per share. The company's overall market value remains unchanged, but this tactic is often a lifeline, helping firms stay in compliance with exchange rules, like Nasdaq's minimum price requirement, and sidestep the risk of delisting. Whether the goal is to attract new investors or maintain compliance, these strategic actions send signals that seasoned traders are quick to watch for. Let's take a look at the upcoming stock splits for the week. Salarius Pharmaceuticals (SLRX) – Salarius is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and anemia. On August 14, the company announced a 1-for-15 reverse stock split to regain compliance with Nasdaq's $1.00 minimum bid price requirement. The split took effect on August 15, with split-adjusted trading beginning on August 18. Entero Therapeutics (ENTO) – Entero, a clinical-stage biopharma focused on targeted, non-systemic gastrointestinal (GI) therapies, is taking steps to secure its Nasdaq listing. On August 14, the company unveiled plans for a 1-for-3 reverse stock split, a move designed to keep its shares in compliance with exchange rules. The adjustment becomes effective August 18. Chanson International Holding (CHSN) – China-based Chanson International operates bakery chains and sells packaged bakery products, frozen dough, and other food items across domestic and international markets. On August 18, the company will implement an 80-for-1 reverse split to get back in line with Nasdaq's minimum bid price rule. LanzaTech Global (LNZA) – LanzaTech Global uses gas fermentation technology to capture carbon emissions and convert them into sustainable fuels and chemicals, partnering with major industrial players worldwide. The company announced a 1-for-100 reverse stock split to meet Nasdaq listing standards, with the split taking effect on August 18, and split-adjusted trading beginning on August 19. GIBO Holdings (GIBO) – GIBO Holdings, headquartered in Singapore, operates an AI-driven animation and entertainment streaming platform that produces and distributes original content while also offering digital media services. The company announced a 200-for-1 reverse split to streamline its capital structure and stay in line with listing requirements, with the split taking effect on August 20. Azitra (AZTR) – Azitra is a clinical-stage biotech company developing genetically engineered therapies and live biotherapeutics for dermatological conditions such as eczema and rare skin diseases. The company announced the 1-for-6.66 reverse stock split in order to bring its share price back above NYSE American's minimum bid requirement, effective on August 21, 2025.
Yahoo
3 hours ago
- Yahoo
Is Perplexity's $34.5bn bid for Google Chrome strictly a power move?
Artificial intelligence start-up Perplexity AI has made an unsolicited $34.5bn (£25.4bn) all-cash offer for Google's Chrome browser, in a move that some analysts say is as much about signalling intent as it is about striking a deal. The San Francisco-based company revealed the bid on Tuesday, reported Reuters, claiming it had secured backing from several large venture capital funds to finance the offer in full, although it did not name them. Chrome, launched in 2008, is used by more than three billion people worldwide and remains a cornerstone of Google's control over online search. The timing is notable, with Perplexity's approach coming our just weeks before US District Judge Amit Mehta is expected to outline remedies in a major antitrust case the Department of Justice (DOJ) won against Google last year. The DOJ has proposed that Chrome be divested to restore competition, though Google has vowed to appeal, describing the remedies as 'extraordinary' and 'overboard'. Strategic positioning in the AI search race Perplexity, valued at $18bn in its latest funding round, is one of a wave of AI-powered search challengers seeking to disrupt the traditional search market. Founded in 2022, the firm's search engine provides AI-generated direct answers alongside links to source material, and in July it launched Comet, its own browser built on the same open-source platform as Chrome. In its bid, Perplexity pledged to keep the open source platform, Chronium, invest $3bn in Chrome over two years, retain most of the browsers' staff and, notably, keep Google as the default search engine. Ben Barringer, global tech analyst at Quilter Cheviot, said the offer 'is as much about making a statement as it is about securing a deal', noting the $34.5bn price tag 'is widely seen as undervaluing Chrome' and could be the start of a broader price discovery process. The move also highlights the growing strategic value of browsers in the AI era. 'Whoever owns the gateway to the web holds influence over how information is accessed, prioritised, and trusted', said Alon Yamin, co-founder and chief executive of Copyleaks. Whether the bid is a realistic attempt or a calculated show of strength, analysts expect any forced Chrome sale to attract multiple suitors like OpenAI and Yahoo, if regulators push ahead. But Google is likely to fight any divestment through a lengthy appeals process, potentially delaying such a decision for years.
Yahoo
3 hours ago
- Yahoo
I'm a psychologist who coaches day traders. Here's why many fail and what I tell them to do instead
Andrew Menaker is a psychologist who now coaches day traders on and off Wall Street. Menaker thinks many traders struggle for a common set of reasons, like having too big an ego. A day trader himself, he has a few tips for people — literally — trying to get in on the trade. This as-told-to essay is based on a conversation with Andrew Menaker, a psychologist and a day trading coach based in San Francisco. It has been edited for length and clarity. First of all, I had never, ever planned on becoming a trading psychology coach. In fact, many years ago, I never knew anything about markets. I think I had one econ class in undergrad. That was it. I actually started my career at the US Navy as an independent psychological consultant. My job was to work with agencies like the NCIS, the FBI, and the Secret Service and to help with things like threat assessments and hostage negotiations. I felt like an impostor, coming right out of grad school, but I seemed to be a natural for it. I got very lucky. Wells Fargo heard about my reputation in the Navy, and, after a post-doc internship with them, I was hired as a psychological consultant on their trading desk. Again, I felt like an impostor — no background in finance, brand new Ph.D. Here I am, green behind the ears. But the people at Wells Fargo saw something in me. My very first clients were institutional desk traders who were moving hundreds of millions of dollars at the push of a button. It was the first time I had been exposed to trading. After several years of consulting on Wall Street, I started trading on my own. It was the '90s in San Francisco during the dot-com bubble. Stocks were starting to race up. The market bug bit, and I thought, "Oh my gosh, this is something for me. I've got to do this for myself." Back in those days, all stocks were going up, so it was kind of easy. My brokerage account went from $25,000 to $150,000 over a six-month period, and I was featured in a book about my trading success. I still trade today. Now, I run my own coaching practice, where I work with traders of all sorts — Wall Street traders, prop traders, and even retail traders, some of whom are aiming to go full-time. People usually come to me with some kind of trading issue: "I can't follow my plan." "I'm having a hard time accepting losses." "I'm over-trading." What many people don't realize is that they're not just trading in a vacuum, whether they're on a bank desk or in a hedge fund or trading their own money. Your whole life comes with you into every trade, whether you consciously realize it or not. My job is to help people understand that. I call it trading your "inner market." It's comprised of biological influences — your sleep, your hormone levels — as well as your emotions — your thoughts, your memories, your experiences in life, how people see you, and how you want to be seen by others. When a trader understands how their inner market operates, they start to see the market on the screen differently. By default, I end up becoming a life coach for many of my clients. I'm helping them, not just with their trading, but with marriages, divorces, having children, all kinds of stuff. Here are some of the most common issues I see hold traders back — and what I recommend traders do instead. Big ego When I was featured in a book about my trading success, I was one of 16 top traders that was featured. That really puffed up my ego. But within weeks of that book coming out, my trading went downhill. I had the biggest drawdown of my career. I talk about this often with my clients. I call it the recognition trap. The fame and the pressure that comes with it can smell trouble for your performance, and that certainly happened to me. Some of my clients might know that their ego is too big. But it often requires somebody else — someone credible that they trust — to actually point it out to them. Too aggressive Around 70%-80% of my retail clients are too aggressive in taking risks. They tend to put on too many trades. They tend to be impulsive. They can't wait for the moment when their plan says they should be getting into the market. And, when they lose money, they want to make it back as quickly as possible. So they start revenge trading, which usually makes things worse. Too scared There are some clients who are very frozen-deer-in-the-headlights. I see this often when I work with traders who are software engineers. Their background is all about precision, black and white, right or wrong. Unless it's perfect, they're not going to want to pull the trigger. Well, markets are never perfect. They're kind of messy. So people who tend to be more on the risk-averse side, they tend to be the under-traders. Solutions Journaling. All traders should be keeping what I call a real-time emotion journal. Ask yourself questions while you're engaged with the market. What am I feeling right now? Why am I feeling this way? When I feel this way, what do I typically do? Write that out and answer it. Many traders get pulled into the market. They're staring at the screen and feel that they have no choice but to execute the trade. But you always have a choice. This type of reflection can help people recognize when they're under pressure. They don't have to hit the button so automatically. Regulate your nervous system. When you're feeling anxious, the limbic system will generate the flight, fight, or freeze response. We all have it. But that instinct often translates into hitting the button on your keyboard at the wrong time. If you can relax, the response won't be quite as extreme. You can downregulate your nervous system by tracking heart rate variability with a monitor. If you don't have that, you can simply take slow, long breaths when you're under pressure. Be aware of your health. When I take on a new client, I explore their physiology with them. What's your diet like? What's your exercise routine? How much sleep are you getting? All of that filters into how we see the market and how we interact with it. If you didn't sleep much last night, be really careful about putting on trades. I've seen it with myself and my clients. There's a correlation between sleep deprivation and sloppy trading. Are you a day trader and want to share your story? Reach out to this reporter at jsor@ Read the original article on Business Insider
